Umbilical Cord Blood is taken from the placenta after birth as well as from the newborn baby's umbilical cord. It is enriched with adult stem cells, which are crucial for developing tissues and controlling all biological processes in the human body.
Covid-19 Impact & Market Status
The global market for umbilical cord blood, particularly in the early years, has been negatively impacted by the COVID-19 pandemic outbreak. All endoscopic procedures worldwide were subject to a time limit due to the introduction of global lockdown. A few hospital departments were opened with a small staff while the majority were shut down in order to uphold social distance norms. However, once the lockdown is fully lifted, the world market for umbilical cord blood will begin to recover at a steady rate.
The segment with the biggest share
The market is divided into Autologous Transplant, Allogenic Transplant, Stem Cell Transplant, Regenerative Medicine, Transplant Medicine, and Others based on the type of product it offers. The Stem Cell Transplant segment holds the big market share. Umbilical cord blood, which is disposed after labor and delivery or pregnancy, represents one of the top sources of stem cells. However, there is significant promise for this blood to cure long-term conditions like cancer, diabetes, blood illnesses, and immunological disorders. Need and advancement in medical technologies are the driving factors for the growth in this segment.
Public and Private Cord Blood Banks segment
The market is segmented into Academic Institutes, Therapeutics Service Companies, Public and Private Cord Blood Banks, Research-Based Pharmaceutical Companies, and Others based on the distribution channel. The market share that belongs to Public and Private Cord Blood Banks is the largest. The fact that UCB may be stored for later use and so offers a ready-made solution for people in dire need of a transplant is one of its most enticing features. As seen by the UCB industry's explosive growth in the first decade of this century, this has resulted in the establishment of publicly supported, privately owned, and publicly traded UCB banks.
North America segment accounted for the Largest CAGR
Based on Regional Analysis, The Global Umbilical Cord Blood (UCB) Stem Cell Market is classified into Europe, Asia Pacific, North America, Middle East and Africa, and the South America. During the projected period, the North America area is predicted to experience the highest CAGR. Moreover, Asia Pacific is expected to grow in the upcoming year owing to living advancement and modernization in the region.
The market for umbilical cord blood is expanding significantly on a global scale as a result of the rising prevalence and incidence of chronic diseases as well as the development of regenerative treatments.
The demand for an affordable and effective treatment approach has increased due to the sharp increase in chronic diseases such diabetes, blood disorders, cancer, metabolic diseases, immunological diseases, etc. The blood that stays in the placenta and the associated umbilical cord after childbirth is known as umbilical cord blood (UCB). To preserve the viability and potential of the cell product, it is manufactured and kept in either liquid-phase nitrogen or nitrogen in the vapor phase. Because UCB contains stem cells that are utilized to treat genetic and hematological diseases, it is harvested.
Hematopoietic stem cells can be extracted from bone marrow or mobilized into peripheral circulation, but umbilical cord blood (UCB), which is abundant in HSCs, is a more appealing option. The fact that UCB may be stored for later use and so offers a ready-made solution for people in dire need of a transplant is one of its most enticing features.
The key reason propelling the growth of the umbilical cord blood (UCB) stem cell market is the fact that umbilical cord blood stem cells have the ability to cure these chronic diseases successfully. Additionally, after umbilical cord blood stem cell transplants, test values for the production of white blood cells and platelets grow more slowly than they do after bone marrow stem cell transplants. This element could potentially slow the market's expansion, according to predictions. The expansion of the market in industrialized nations is significantly influenced by the price of stem cell therapy.
As a rich source of hematopoietic stem cells, cord blood is currently able to treat more than 80 hereditary disorders. As well as funding investments in medical activities for research and commercialization of umbilical cord blood stem cells for large-scale treatment, numerous government organizations are currently sponsoring studies and clinical trials of stem cells in the cord blood. Furthermore, due of the fierce rivalry in the market, businesses are scrambling to build their brands, which has forced operators to utilize a number of on-market tactics.
However, compared to bone marrow stem cell transplants, umbilical cord blood stem cell transplants take longer for the lab values for the production of white blood cells and platelets to increase. This element could potentially slow the market's expansion, according to predictions. The expansion of the UCB banking business is further constrained by stringent licensing and accreditation requirements. The expansion of the market in industrialized nations is significantly influenced by the price of stem cell therapy.
The market for umbilical cord blood is estimated to reach USD 12.16 billion by 2029 and expand at a CAGR of 16.68% over the projected timeframe.
Cytori, Mesoblast, ATCC, NeoStem, Opexa Therapeutics, Therapeutics, Osiris Therapeutics, Caladrius Biosciences, Pluristem Therapeutics, Smart Cells International, Advanced Cell Technology, Athersys, Cord Blood Registry Systems, and California Stem Cell are a few of the major companies active in the global umbilical cord blood market. These businesses have used strategies like alliances, mergers, and acquisitions, among others, to expand in the worldwide umbilical cord blood market.
Latest Innovations in the Global Radiology Information System Market: A Snapshot
- In January 2022, Leading biotechnology business Pluristem Therapeutics has announced the beginning of an innovative partnership with Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, (collectively, "Parties") to create, produce, and market cultured cell-based goods for the food sector. In order to utilise Pluristem's patented technology, intellectual property, and know-how in the field of cultured meat, the partnership began with the incorporation of a new business ("NewCo"). This firm will be granted exclusive, worldwide, royalty-bearing license rights to do so.
- The closing of the acquisition by Smith & Nephew plc was announced by Osiris Therapeutics in April 2019. Osiris merged with Smith & Nephew and became a wholly indirect subsidiary of that company (the "Subsidiary").
Umbilical Cord Blood Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2030||USD 12.16 billion|
|Growth Rate||CAGR of c % during 2021-2030|
|Segment Covered||Product Type, Distribution Channel, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Cytori, Mesoblast, ATCC, NeoStem, Opexa Therapeutics, Therapeutics, Osiris Therapeutics, Caladrius Biosciences, Pluristem Therapeutics, Smart Cells International, Advanced Cell Technology, Athersys, Cord Blood Registry Systems|
Key Segments of the Global Umbilical Cord Blood Market
Product Type Overview, 2019-2029 (USD Billion)
- Regenerative Medicine
- Transplant Medicine
- Allogenic Transplant
- Autologous Transplant
- Stem Cell Transplant
Distribution Channel Overview, 2019-2029 (USD Billion)
- Public and Private Cord Blood Banks
- Research-Based Pharmaceutical Companies
- Academic Institutes
- Therapeutics Service Companies
Regional Overview, 2019-2029 (USD Billion)
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
Middle East and South Africa